This data article contains extended, complementary analysis related to the research articles entitled "Desmoglein 3, via an interaction with E-cadherin, is associated with activation of Src" (Tsang et al., 2010) [1] and figures related to the review article entitled "Desmoglein 3: a help or a hindrance in cancer progression?" (Brown et al., 2014) [2]. We show here that both Src and caveolin-1 (Cav-1) associate with Dsg3 in a non-ionic detergent soluble pool and that modulation of Dsg3 levels inversely alters the expression of Src in the Cav-1 complex. Furthermore, immunofluorescence analysis revealed a reduced colocalization of Cav-1/total Src in cells with overexpression of Dsg3 compared to control cells. In support, the sequence analysis has identified a region within the carboxylterminus of human Dsg3 for a likelihood of binding to the scaffolding domain of Cav-1, the known Src binding site in Cav-1, and this region is highly conserved across most of 18 species as well as within desmoglein family members. Based on these findings, we propose a working model that Dsg3 activates Src through competing with its inactive form for binding to Cav-1, thus leading to release of Src followed by its auto-activation.
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This data article contains extended, complementary analysis related to the research articles entitled "Desmoglein 3, via an interaction with E-cadherin, is associated with activation of Src" (Tsang et al., 2010) [1] and figures related to the review article entitled "Desmoglein 3: a help or a hindrance in cancer progression?" (Brown et al., 2014) [2] . We show here that both Src and caveolin-1 (Cav-1) associate with Dsg3 in a non-ionic detergent soluble pool and that modulation of Dsg3 levels inversely alters the expression of Src in the Cav-1 complex. Furthermore, immunofluorescence analysis revealed a reduced colocalization of Cav-1/total Src in cells with overexpression of Dsg3 compared to control cells. In support, the sequence analysis has identified a region within the carboxylterminus of human Dsg3 for a likelihood of binding to the scaffolding domain of Cav-1, the known Src binding site in Cav-1, and this region is highly conserved across most of 18 species as well as within desmoglein family members. Based on these findings, we propose a working model that Dsg3 activates Src through competing with its inactive form for binding to Cav-1, thus leading to release of Src followed by its auto-activation. 
Data
The desmosomal cadherin, Desmoglein 3 (Dsg3) is a calcium-dependent adhesion protein in epithelial cells and has recently been identified to associate with E-cadherin/Src and act as an upstream regulator in E-cadherin/Src signaling [1] [2] [3] [4] [5] . However, the molecular mechanism by which Dsg3 regulates Src remains poor understood. In vitro study showed that Dsg3 is internalized through a lipid raft-mediated pathway upon PV-IgG binding [6] and lipid raft contains caveolin protein. Interestingly, the Dsg3 associated family member Dsg2 is recently found to interact directly with the scaffold domain of caveolin-1 [7] . Hence, we speculated that Dsg3 also forms a complex with caveolin-1 along with Src. To investigate this possibility, we performed co-IP experiments with mouse antibody against Dsg3 in Triton-soluble and insoluble fractions of HaCaT cells, respectively, using the same procedures as previously described [1, 4] . Western blotting of immunoprecipitates revealed that both caveolin-1 and Src co-purified with Dsg3, alongside E-cadherin and actin, in particular from Triton-soluble fraction (Fig. 1A) . The proximity ligation assay (PLA) showed that, compared with the negative control, there was a substantial increase of PLA signals in cells probed with either Dsg3/ caveolin-1 or Dsg3/Src antibody combinations (Fig. 1B left bar chart) and Dsg3 silencing resulted in a reduced PLA signals as expected (data not shown).
Several lipid-regulated signaling molecules, including Src, Gα subunits and H-Ras, bind caveolin [8, 9] . Src of inactivated form is identified to bind to a membrane-anchored scaffolding domain of caveolin; the 20aa stretch within a membrane-proximal region of the cytosolic N-terminal domain of caveolin [8] (see cartoon in Fig. 5B ). This 20aa residues functionally inhibit the auto-activation of c-Src and Fyn tyrosine kinases [8] . Hence, we hypothesized that Dsg3 may compete with inactive Src for the same binding site on caveolin. To test this hypothesis, we analyzed the immune complexes purified with caveolin-1 antibody in A431-Vect control and A431-hDsg3.myc cells with overexpression of Dsg3. Western blotting of caveolin-1 immunoprecipitates showed that overexpression of Dsg3 increased its association with caveolin-1 while reducing the amounts of Src in such a complex, compared to vector control cells (Fig. 1C  left panels) . In parallel, co-IP was performed in HaCaTs with or without Dsg3 depletion. Western blotting analysis of immunoprecipitates showed that Dsg3 silencing resulted in an increase in the amount of Src in the complex purified by caveolin-1 antibody (Fig. 1C right panels) . Furthermore, confocal analysis indicated enhanced co-localization of Dsg3 and caveolin-1 at the plasma membrane in cells with overexpression of Dsg3 relative to vector control cells (Fig. 1D) .
To test our hypothesis further, we performed double immunostaining with antibody combination for Cav-1/phospho-Src and Cav-1/total Src, respectively, followed by colocalization analysis with ImageJ. As shown in Fig. 2 , there was little colocalization for Cav-1/pSrc at the cell borders in A431 cells and pSrc was predominantly expressed in the membrane protrusions. However, a marked increase in the colocalization of Cav-1 and total Src was detected at the cell borders in A431-V cells but this was found to be reduced in Dsg3 overexpressing cells (A431-D3) (see the colocalization images and profiles in Fig. 2B ). Interestingly, a reduced expression level of Cav-1 was also observed in A431-D3 cells compared to A431-V control in which an enhanced Cav-1 staining at cell borders was noticeable.
The protein sequence analysis identifies a putative region for binding the caviolin-1 scaffolding domain enriched in aromatic amino acids [10] in Dsg3 which is highly conserved across most of 18 species (Fig. 3) as well as within the Dsg family members (Fig. 4) . This potential binding site is located within the ICS domain of C-terminus of Dsg3 at 788-798aa, an 11aa stretch which contains 4 aromatic aa residues and which likely competes with the inactive Src for binding to the scaffolding domain in caveolin-1 [10] . Interestingly, this region is overlapped with previously identified segment by Andi and Stanley [11] , the 87aa sequence within the ICS domain downstream from the 779aa, that is Alignment of Dsg3 across 18 species using the program MUSCLE [14] . The putative binding site (box with red line), at amino acid sequence between 788-798 with four aromatic amino acid residues (asterisks), for the scaffolding domain of caveolin-1 [10] is depicted to be conserved across 10 of 18 species. The amino acids are coloured according to the Clustal X Colouring Scheme [15] . required for binding to plakoglobin and recruitment of Dsg3 to desmosomes. Study based on plakoglobin null keratinocytes by Green and colleagues has suggested that plakoglobin plays a role to suppress Src activity [12] . Thus it is possible that when plakoglobin is ablated the excess free Dsg3 molecules compete with Src for binding the scaffolding domain of caveolin-1 thus elicits Src autoactivation. In accord, when Dsg3 is overexpressed the same result would occur with a consequence of Src activation. A A P HP GD   735  734  735  735  734  734  764  734  735  735  748  677  657  747  757  768  784  784   816  815  816  816  799  809  831  803  795  794  809  706  720  807  819  794  810  810 A 891  890  891  891  874  884  907  878  874  868  884  783  793   949  948  949  949  933  943  965  938  944  926  952  850  853 - 950  949  950  950  934  944  966  939  945  927  953  851  854   999  981  999  1003  983  993  1015  988  993  975  1005  900  905 
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Based on these findings we have proposed a working model that Dsg3 competes with inactive Src for binding to the scaffolding domain of caveolin-1, and thus causes Src to release from binding to caveolin-1, that leading to its auto-activation (Fig. 5B ). This working model opens up a new avenue for future research. Fig. 4 . The putative binding site is conserved within human Dsg subfamily. The four family members of human Dsgs were aligned using the program MUSCLE [14] . The putative binding site for the scaffolding domain of caveolin [10] is highlighted in the box with a dotted line, in which four aromatic amino acid residues are depicted to be highly conserved across the family members (asterisks).
Experimental design, materials and methods
Antibodies
The mouse monoclonal and rabbit polyclonal Abs used were: 5H10, mouse Ab against Dsg3 (Santa Cruz Biotechnology, Inc); HECD-1, mouse anti-E-cadherin (Abcam); Src (32G6) rabbit mAb and phospho-Src family (Tyr416) (Cell Signaling); rabbit caveolin-1 Ab (Cell Signaling); mouse mAb against caveolin-1 (Santa Cruz Biotechnology); rabbit anti beta actin-loading control ab8227 (Abcam); Secondary Abs were Alexa Fluor 488 conjugated goat anti-mouse IgG and Alexa Fluor 546 conjugated goat anti-rabbit IgG (Invitrogen).
Transient Dsg3 siRNA transfection
The siRNA sequence corresponding to nucleotides 620-640 of the respective coding region in human Dsg3 mRNA (Accession: NM_001944.1) (AAATGCCACAGATGCAGATGA) was used to knockdown Dsg3. The scrambled control siRNA was a randomized sequence of RNAi (AACGATGATA-CATGACACGAG). Both sequences were synthesized by Dharmacon Research (USA). The transfection procedures were described previously [13] .
Co-immunoprecipitation (co-IP) and Western blotting
For analysis of protein in Triton X-100 -soluble and -insoluble fractions, cells were grown to freshly confluence in 100 mm Petri dishes prior to protein extraction in 500 ml of Trition X-100 lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM ethyleneglycol-bis-(β-aminoethylether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), 5 mM ethylenediamine tetraacetic acid (EDTA), 1%Triton X-100, 1 mM phenylmethylsufonyl fluoride and protease inhibitor cocktail (Boehringer Mannheim)) for 10 min at 4°C. After centrifugation the supernatant was denoted as the Triton X-100 soluble fraction and the undissolved pellet subsequently was extracted in 200 ml RiPA buffer. After centrifugation the supernatant was collected and lysate was denoted as the Triton X-100 insoluble fraction. Protein concentration for each fraction was determined. 500 mg of protein in each fraction was used for co-IP experiment. For total cell lysate preparation, confluent cell cultures were washed with ice-cold PBS and lysed in ice cold RIPA buffer (Upstate) containing a protease-inhibitor cocktail (Calbiochem), for 10 min at 4°C. Then lysates were clarified by microcentrifugation. The amount of 500 mg of total protein in each sample, as determined by DC protein assay (Bio-Rad), was used for IP. The rabbit caveolin antibody were coupled with Dynabeads (Invitrogen) for 3 h before addition into each lysate and incubated overnight at 4°C with rotation. Immunoprecipitates were washed thoroughly prior to resuspension in 2 Â Laemmli sample buffer and boiled for 3 min. Aliquots of the denatured proteins were separated by SDS-PAGE and processed for Western blotting.
Duolink in situ proximity ligation assay for protein:protein interactions
Duolink proximity ligation assay (PLA) kit, composed of anti-mouse PLA probe plus, anti-rabbit PLA probe minus and detection kit 563, was purchased from Olink Bioscience (Cambridge Bioscience, UK). PLA assay was conducted following the protocol described with the kit. Briefly, cells grown on coverslips were fixed and then blocked with 10% goat serum (Sigma) for 15 min followed by incubation with primary antibody for 1 h at 37°C. After this, coverslips were subjected to sequential incubation with PLA (plus þminus) probes for 2 h, hybridization for 15 min, ligation with ligase for 15 min, amplification with polymerases for 90 min and finally detection for 1 h. All these incubations were carried out at 37°C and the coverslips were washed with 1 Â TBS-T under gentle agitation for 2-5 min between each incubation step. Finally, the samples were mounted and analyzed using a Leica DM5000 epi-fluorescence microscope. The negative control in this assay was A431-V cells labeled with mouse Dsg3 Ab (5H10) and rabbit anti-Myc tag Ab. The experimental samples were HaCaT cells labeled with mouse Dsg3 (5H10) and rabbit Cav-1 Ab or rabbit anti-Src, respectively. Statistical analysis was performed with Student's t-test and p o0.05 was considered statistically significant.
Immunofluorescence, confocal microscopy and colocalization analysis
For confocal analysis, cells were seeded at confluent or sub-confluent density on coverslips for one day. Then, cells were fixed with ice cold methanol and immune-fluorescently labeled using the mouse Dsg3 Ab (5H10)/ rabbit anti-caveolin-1 (in Fig. 1D ) or the indicated antibody combinations (in Fig. 2 ). Coverslips were blocked with 10% goat serum for 20 min before the primary antibody incubation for 1 h at room temperature, followed by three washes for 5 min in PBS with 0.2% Tween 20. The secondary antibodies were Alexa 488 mouse IgG/ Alexa 546 rabbit IgG (Fig. 1D) or Alexa 488 rabbit IgG/ Alexa 546 mouse IgG (Fig. 2 ) and all were incubated for 1 h at room temperature. After two washes, coverslips were counterstained with DAPI for 10 min before a final wash and then mounted on slide. All antibodies were diluted at 1:100 in blocking buffer. Image stacks were acquired with Zeiss510 confocal microscope and analyzed with ImageJ for image processing and colocalization of double stained proteins. The presented images in Fig. 1D were Z projection with maximum intensity and in Fig. 2 were single confocal slice acquired at the highest protein expressing level in each region. The Colocalization Finder tool was used for colocalization analysis and the profiles of IMF staining at the cell borders were analyzed with a Segmented Lines tool with a line width of 20 pixels. All graphs were plotted in Excel.
Protein sequence alignment
The protein sequence alignment analysis was performed using the MUSCLE program [14] . The amino acids are colored according to the Clustal X Coloring Scheme [15] .
